AstraZeneca Released New Numbers Regarding Recent Trial

Yesterday, AstraZeneca updated the data numbers from it’s recent trial. Their new report says the vaccine is 76% effective in preventing symptomatic Covid-19 cases and 100% effective against severe or critical disease or the need of hospitalization. The vaccine was 85% effective in preventing symptoms in volunteers 65 and older.  On Monday, AstraZeneca said their vaccine showed it was 79% effective against symptomatic disease and 100% effective against severe disease and hospitalization. The company revealed numbers during a news release and not in a peer-reviewed report or as a formal submission for the U.S. Food and Drug Administration. On Tuesday, the Independent Data and Safety Monitoring Board that reviews data from Covid-19 candidates expressed concern over AstraZeneca’s announcement of it’s latest findings and the National Institute of Allergy and Infectious Diseases announced those concerns publicly giving the company 48 hours to present data.